# Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation

> **NCT00642655** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Kidney Transplant

## Interventions

- **DRUG:** IVIG and Rituximab

## Key facts

- **NCT ID:** NCT00642655
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2008-03-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00642655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00642655, "Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00642655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*